Literature DB >> 35754779

Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Chunhong Dong1, Bao-Zhong Wang1.   

Abstract

Reoccurring seasonal flu epidemics and occasional pandemics are among the most severe threats to public health. Current seasonal influenza vaccines provide limited protection against drifted circulating strains and no protection against influenza pandemics. Next-generation influenza vaccines, designated as universal influenza vaccines, should be safe, affordable, and elicit long-lasting cross-protective influenza immunity. Nanotechnology plays a critical role in the development of such novel vaccines. Engineered nanoparticles can incorporate multiple advantageous properties into the same nanoparticulate platforms to improve vaccine potency and breadth. These immunological properties include virus-like biomimicry, high antigen-load, controlled antigen release, targeted delivery, and induction of innate signaling pathways. Many nanoparticle influenza vaccines have shown promising results in generating potent and broadly protective immune responses. This review will summarize the necessity and characteristics of next-generation influenza vaccines and the immunological correlates of broad influenza immunity and focus on how cutting-edge nanoparticle technology contributes to such vaccine development. The review will give new insights into the rational design of nanoparticle universal vaccines to combat influenza epidemics and pandemics.

Entities:  

Keywords:  Universal influenza vaccines; cross-protection; nanoparticles; vaccine delivery

Year:  2021        PMID: 35754779      PMCID: PMC9231845          DOI: 10.1002/anbr.202100122

Source DB:  PubMed          Journal:  Adv Nanobiomed Res        ISSN: 2699-9307


  178 in total

1.  Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection.

Authors:  Tao Wu; Yinghong Hu; Young-Tae Lee; Keith R Bouchard; Alexandre Benechet; Kamal Khanna; Linda S Cauley
Journal:  J Leukoc Biol       Date:  2013-09-04       Impact factor: 4.962

2.  Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.

Authors:  Lisa M Dunkle; Ruvim Izikson; Peter Patriarca; Karen L Goldenthal; Derek Muse; Janice Callahan; Manon M J Cox
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

3.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

4.  Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation.

Authors:  Hannah G Kelly; Hyon-Xhi Tan; Jennifer A Juno; Robyn Esterbauer; Yi Ju; Wenbo Jiang; Verena C Wimmer; Brigette C Duckworth; Joanna R Groom; Frank Caruso; Masaru Kanekiyo; Stephen J Kent; Adam K Wheatley
Journal:  JCI Insight       Date:  2020-05-21

5.  Toll-like Receptor 4 Engagement on Dendritic Cells Restrains Phago-Lysosome Fusion and Promotes Cross-Presentation of Antigens.

Authors:  Andrés Alloatti; Fiorella Kotsias; Anne-Marie Pauwels; Jean-Marie Carpier; Mabel Jouve; Evy Timmerman; Luigia Pace; Pablo Vargas; Mathieu Maurin; Ulf Gehrmann; Leonel Joannas; Omar I Vivar; Ana-Maria Lennon-Duménil; Ariel Savina; Kris Gevaert; Rudi Beyaert; Eik Hoffmann; Sebastian Amigorena
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

Review 6.  Recent progress of graphene oxide as a potential vaccine carrier and adjuvant.

Authors:  Wanjun Cao; Lin He; Weidong Cao; Xiaobing Huang; Kun Jia; Jingying Dai
Journal:  Acta Biomater       Date:  2020-06-10       Impact factor: 8.947

7.  Graphene Oxides Decorated with Carnosine as an Adjuvant To Modulate Innate Immune and Improve Adaptive Immunity in Vivo.

Authors:  Chunchun Meng; Xiao Zhi; Chao Li; Chuanfeng Li; Zongyan Chen; Xusheng Qiu; Chan Ding; Lijun Ma; Hongmin Lu; Di Chen; Guangqing Liu; Daxiang Cui
Journal:  ACS Nano       Date:  2016-01-19       Impact factor: 15.881

8.  Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.

Authors:  Chunhong Dong; Ye Wang; Gilbert X Gonzalez; Yao Ma; Yufeng Song; Shelly Wang; Sang-Moo Kang; Richard W Compans; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 11.205

9.  Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.

Authors:  Hao Feng; Han Zhang; Jiusheng Deng; Li Wang; Yuan He; Shelly Wang; Roheila Seyedtabaei; Qing Wang; Laiting Liu; Jacques Galipeau; Richard W Compans; Bao-Zhong Wang
Journal:  Sci Rep       Date:  2015-07-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.